These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16606956)

  • 1. Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?
    Hiralal R; Koo KK; Gerstein HC
    CMAJ; 2006 Apr; 174(8):1090-1. PubMed ID: 16606956
    [No Abstract]   [Full Text] [Related]  

  • 2. [Glucose-independent impact of the glitazones on the cardiovascular outcome].
    Hanefeld M
    MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone: a review of its use in type 2 diabetes mellitus.
    Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
    Drugs; 2006; 66(1):85-109. PubMed ID: 16398569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prospective pioglitazone clinical trial in macrovascular events].
    Asanuma H; Kitakaze M
    Nihon Rinsho; 2012 May; 70 Suppl 3():301-8. PubMed ID: 22768537
    [No Abstract]   [Full Text] [Related]  

  • 5. [Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients].
    Scheen AJ; Lefèbvre PJ
    Rev Med Liege; 2005 Nov; 60(11):896-901. PubMed ID: 16402538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
    Charbonnel B; Dormandy J; Erdmann E; Massi-Benedetti M; Skene A;
    Diabetes Care; 2004 Jul; 27(7):1647-53. PubMed ID: 15220241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pioglitazone. Review of its metabolic and systemic effects].
    Rodríguez Bernardino A; Cebrián Blanco S; Durán García S
    Rev Clin Esp; 2005 Dec; 205(12):610-20. PubMed ID: 16527183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.
    Pfützner A; Forst T
    Expert Opin Pharmacother; 2006 Mar; 7(4):463-76. PubMed ID: 16503818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.
    Schernthaner G; Currie CJ; Schernthaner GH
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S155-61. PubMed ID: 23882041
    [No Abstract]   [Full Text] [Related]  

  • 10. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
    Stolar MW; Chilton RJ
    Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
    Simó R; Rodriguez A; Caveda E
    Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
    JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?
    Singaram V; Pratley R
    Diab Vasc Dis Res; 2007 Sep; 4(3):237-40. PubMed ID: 17907116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
    Holleman F; Gerdes VE; de Vries JH; Hoekstra JB
    Ned Tijdschr Geneeskd; 2006 Feb; 150(7):358-60. PubMed ID: 16523797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.
    Nishio K; Shigemitsu M; Kodama Y; Konno N; Katagiri T; Kobayashi Y
    Cardiovasc Revasc Med; 2009; 10(1):5-11. PubMed ID: 19159848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
    Genovese S; De Berardis G; Nicolucci A; Mannucci E; Evangelista V; Totani L; Pellegrini F; Ceriello A
    Adv Ther; 2013 Feb; 30(2):190-202. PubMed ID: 23359066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
    Khan M; Xu Y; Edwards G; Urquhart R; Mariz S
    Int J Clin Pract; 2004 Oct; 58(10):907-12. PubMed ID: 15587767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organ protection in the secondary prevention of type 2 diabetes.
    Schernthaner G
    Drugs Today (Barc); 2006 Dec; 42 Suppl C():17-23. PubMed ID: 17245477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.